Ketek

Shares of Cempra Inc (NASDAQ: CEMP) plunged 60 percent to a new 52-week low of $7.35 after FDA briefing documents questioned whether solithromycin has some of the same safety risks as Ketek and potential for liver toxicity. The FDA issue came on the heels of company announcing the receipt of a $10...